These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 2371298)

  • 21. Integration of Pig-a, micronucleus, chromosome aberration, and Comet assay endpoints in a 28-day rodent toxicity study with 4-nitroquinoline-1-oxide.
    Stankowski LF; Roberts DJ; Chen H; Lawlor T; McKeon M; Murli H; Thakur A; Xu Y
    Environ Mol Mutagen; 2011 Dec; 52(9):738-47. PubMed ID: 22020836
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biological monitoring of aromatic amines and their metabolites using short-term tests for carcinogenicity.
    Garner RC
    IARC Sci Publ; 1981; (40):33-50. PubMed ID: 7035351
    [No Abstract]   [Full Text] [Related]  

  • 23. [Genotoxic and clastogenic effects of doxorubicin].
    Villani P; Orsière T; Duffaud F; Digue L; Bouvenot G; Botta A
    Therapie; 1998; 53(4):391-5. PubMed ID: 9806010
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Guidelines for the testing of chemicals for mutagenicity. Committee on Mutagenicity of Chemicals in Food, Consumer Products and the Environment.
    Rep Health Soc Subj (Lond); 1989; 35():1-99. PubMed ID: 2641173
    [No Abstract]   [Full Text] [Related]  

  • 25. Validity of in vitro testing.
    Matula TI
    Drug Metab Rev; 1990; 22(6-8):777-87. PubMed ID: 2102456
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An analysis of pharmaceutical experience with decades of rat carcinogenicity testing: support for a proposal to modify current regulatory guidelines.
    Sistare FD; Morton D; Alden C; Christensen J; Keller D; Jonghe SD; Storer RD; Reddy MV; Kraynak A; Trela B; Bienvenu JG; Bjurström S; Bosmans V; Brewster D; Colman K; Dominick M; Evans J; Hailey JR; Kinter L; Liu M; Mahrt C; Marien D; Myer J; Perry R; Potenta D; Roth A; Sherratt P; Singer T; Slim R; Soper K; Fransson-Steen R; Stoltz J; Turner O; Turnquist S; van Heerden M; Woicke J; DeGeorge JJ
    Toxicol Pathol; 2011 Jun; 39(4):716-44. PubMed ID: 21666103
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mutagenicity assessment of acrylate and methacrylate compounds and implications for regulatory toxicology requirements.
    Johannsen FR; Vogt B; Waite M; Deskin R
    Regul Toxicol Pharmacol; 2008 Apr; 50(3):322-35. PubMed ID: 18346829
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of rodent carcinogens and noncarcinogens using genetic toxicity tests: premises, promises, and performance.
    Zeiger E
    Regul Toxicol Pharmacol; 1998 Oct; 28(2):85-95. PubMed ID: 9927558
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Carcinogenicity of medicinal drugs: a survey of IARC monographs.
    Török G; Csík M; Pintér A; Surján A
    Cent Eur J Public Health; 2000 Jul; 8 Suppl():83-5. PubMed ID: 10943485
    [No Abstract]   [Full Text] [Related]  

  • 30. Identification of carcinogenic substances by means of short-term tests in bacteria.
    Quillardet P; McGregor D
    IARC Sci Publ; 1999; (146):487-97. PubMed ID: 10353400
    [No Abstract]   [Full Text] [Related]  

  • 31. International prevalidation study on cell transformation assay. Preface.
    Corvi R; Vanparys P
    Mutat Res; 2012 Apr; 744(1):1-2. PubMed ID: 22387843
    [No Abstract]   [Full Text] [Related]  

  • 32. [Problems in the study of mutagenic effects of environmental factors (review)].
    Mozhaeva TE
    Gig Sanit; 1996; (5):38-40. PubMed ID: 8974934
    [No Abstract]   [Full Text] [Related]  

  • 33. Comments and perspective on the EPA workshop on "The relationship between short-term test information and carcinogenicity".
    Kier LD
    Environ Mol Mutagen; 1988; 11(1):147-57. PubMed ID: 2892675
    [No Abstract]   [Full Text] [Related]  

  • 34. Mutation research, genetic toxicology and environmental mutagenesis.
    Martus HJ; Suter W
    Mutat Res; 2009 Jan; 672(2):135. PubMed ID: 19056513
    [No Abstract]   [Full Text] [Related]  

  • 35. Mouse bone marrow micronucleus assay: relationships with in vitro mutagenicity and rodent carcinogenicity.
    Benigni R
    J Toxicol Environ Health; 1995 Jul; 45(3):337-47. PubMed ID: 7609006
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tungsten carbide-cobalt as a nanoparticulate reference positive control in in vitro genotoxicity assays.
    Moche H; Chevalier D; Barois N; Lorge E; Claude N; Nesslany F
    Toxicol Sci; 2014 Jan; 137(1):125-34. PubMed ID: 24085191
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Studies on the mutagenicity of vesnarinone].
    Hu H; Xing Y; Tao D; Zheng X; Yang Z
    Hua Xi Yi Ke Da Xue Xue Bao; 1991 Jun; 22(2):140-3. PubMed ID: 1786949
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Personal comments on 'Environmental Protection Agency' proposed guidelines for mutagenicity risk assessment.
    Sobels FH
    Mutat Res; 1985 Aug; 147(4):211-6. PubMed ID: 4022034
    [No Abstract]   [Full Text] [Related]  

  • 39. Chromosomal changes.
    Preston RJ
    IARC Sci Publ; 1999; (146):395-408. PubMed ID: 10353396
    [No Abstract]   [Full Text] [Related]  

  • 40. [Mutagenicity studies of miporamicin].
    Sono A; Oyaide K; Suzuki A; Kobayashi Y; Matsumoto K; Yamamoto H
    Jpn J Antibiot; 1989 Nov; 42(11):2506-12. PubMed ID: 2621789
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.